ʻO Gliclazide MV: nā ʻōlelo no ka hoʻohana ʻana, nā analogues a me nā loiloi, nā kumukūʻai ma nā lāʻau lapaʻau o Lūkia

ʻO Gliclazide MV kahi lawena hypoglycemic no ka mālama ʻana i ka maʻi maʻi 2. ʻO Gliclazide ka mea hana ikaika.

ʻO ka moliki hypoglycemic Oral, kahi derony o ka sulfonylurea o ka lua o ka hanauna. Hoʻokomo i ka mea huna o ka insulin e β-cells o ka pancreas.

Hoʻonui ka lāʻau lapaʻau i ka hoʻowalewale o nā kōpili peripheral i ka insulin, e hoʻoulu ai i ka hana o nā hana enanthate intracellular (ma ke ʻano kūikawā, muscle glycogen synthetase). Hoʻololi i ka manawa manawa mai ka manawa o ka ʻai ʻana a i ka hoʻomaka ʻana i ka huna ʻana i ka insulin. Hoʻihoʻi i ka mua o ka neʻe o ka huna ʻana o ka insulin, e hoʻēmi ana i ka hopena o ka postprandial o hyperglycemia.

Hoʻololi ʻo Gliclazide MV i ka adhesion platelet a me ka hoʻohui ʻana, e hoʻolohi ana i ka hoʻomohala ʻana o kahi trombus parietal, a hoʻonui i ka hana vibr folyinolytic. Hoʻohālikelike i ka hoʻokele vascular.

ʻO nā haʻahaʻa koko koko (Cs) a me Cs-LDL
Hoʻonui i ka hoʻonuiʻana i HDL-C,
Hoʻēmi i nā radical manuahi.
Kāohi i ka hoʻomohala ʻana o ka microthrombosis a me atherosclerosis.
Hoʻomaikaʻi i ka microcirculation.
Hoʻēmi i ka maʻi maʻi vascular i ka adrenaline.

Me ka nephropathy maʻi maʻi me ka hoʻohana lōʻihi, aia ka nui i ka emi ʻana o ka proteinuria.

Ke koho ʻana i ka lāʻau lapaʻau, loaʻa ka loaʻa i ka glycemic control i nā pono nui i hoʻoholo ʻole ʻia e nā hopena o ka mālama ʻana me nā lāʻau antihypertensive.

Ka ʻĀina o Gliclazide MV (1 papa):

ʻO ka waiwai koʻikoʻi: gliclazide - 30 a 60 mg,
ʻO nā mea kōkua: hypromellose - 70 mg, colloidal silicon dioxide - 1 mg, microcrystalline cellulose - 98 mg, magnesium stearate - 1 mg.

Nā hōʻailona no ka hoʻohana ʻana

He aha ka mea e kōkua ai i ka Gliclazide MV? Wahi a nā ʻōlelo kuhikuhi, he lāʻau lapaʻau no ka mālama ʻana i ka hōʻemi nui o ka maʻi diabetes mellitus type 2 (non-insulin-dependant) me nā hōʻike mua o ka microangiopathy maʻi maʻi.

Hoʻohui ʻē ʻia no ka mālama ʻana i nā ʻōlohelohe o microcirculatory, ma ke ʻāpana o ka hoʻopulapula paʻakikī, i ka manawa pū me nā mea ʻē aʻe sulfonylurea.

Nā ʻōkuhi no ka hoʻohana ʻana i ka Gliclazide MV (30 60 mg), ka pākuʻi

Kālai ʻia ka lāʻau lāʻau 30 minuke ma mua o kahi pāʻina.

ʻO ka dosis e hōʻike ʻia ai kēlā me kēia lā ʻo Gliclazide e ʻōlelo ʻia e 80 mg i kuhikuhi ʻia e nā ʻōkuhi no ka hoʻohana ʻana; inā pono, e hoʻonui ʻia i ka 160-320 mg i 2 mau puʻupaʻa i māhele ʻia.

Ke kāpae nei i kēlā me kēia mea i ka wikiwiki ʻana o ka glycemia a me nā hola 2 ma hope o ka ʻai ʻana, a me nā hōʻike olakino hou o ka maʻi.

Inā haʻalele ʻoe i kahi maʻi, ʻaʻole hiki iā ʻoe ke lawe i ʻelua papana. Ke hoʻololi nei i kekahi lāʻau lapaʻau hypoglycemic hou, ʻaʻole pono kahi manawa hoʻololi - hoʻomaka ʻia ʻo Gliclazide MB e lawe ʻia i ke lā aʻe.

Malia paha kahi hui me biguanides, insulin, alpha-glucosidase inhibitors. I ka hoʻololiʻana i ka hoʻololi ʻana i ka renal i hōʻemi ʻia, e kau ʻia ana i nā ʻano like like.

I nā poʻe maʻi me ka pilikia o ka hypoglycemia, hoʻohana liʻiliʻi ʻia.

Nā ʻōlelo kikoʻī

I ka mālamaʻana i ka mellitus non-insulin-hilinaʻi, pono e hoʻohana pono ka lāʻau lapaʻau i ka manawa like me ka haʻahaʻa-calorie kahiʻai me ka haʻahaʻa o nā pale.

I ka wā mālama, pono ʻoe e kiaʻi pinepine i nā kukuna o kēlā me kēia lā i nā pae glucose, a me ka pae o ka glucose i loko o ke koko ma kahi ʻōpū ʻole a ma hope o ka ʻai.

Nā hopena hopena

Hoʻomaopopo ka ʻōlelo aʻo i ka hiki o ka hoʻomohala ʻana i nā hopena ʻaoʻao aʻe i ka wā i kuhikuhi ai i ka Gliclazide MV:

Nausea, luaʻi, ʻeha ʻeha,
ʻO Thrombocytopenia, erythropenia, agranulocytosis, hemolytic anemia,
ʻAmelika huakaʻi,
ʻIli ʻia ka ʻili, ʻōlohelohe,
ʻO ka hana hema ʻole
Hoʻopiʻi ʻike ʻia
Hypoglycemia (me kahi overdose).

Nā Hoʻohui

Ua hoʻohālikelike ʻia ʻo Glyclazide MV ma kēia mau hihia:

ʻO ka maʻi diabetes mellitus 1 (ke hilinaʻi-insulin),
Ketoacidosis
ʻO ka precoma Diabetic a me ka coma
Haunu kino a me nā maʻi hepatic,
ʻO ka hypersensitivity i sulfonylureas a me sulfonamides.
ʻO ka hoʻohana like ʻana o ka gliclazide a me nā deridatives imidazole (me ka miconazole) hoʻi.

Ua kuhikuhi ʻia me ka akahele i ka poʻe ʻelemakule, me ka papa o ka lawehala, hypothyroidism, hypopituitarism, maʻi nui o ka artery coronary a me ka atherosclerosis nui, ka uka ʻana o adrenal, ka lōʻihi o ka mālama ʻana me ka glucocorticosteroids.

Ke keu

Hōʻike ʻia ka hōʻailona overdose e ka hypoglycemia - ʻeha, ka ʻeha, ka nāwaliwali nui, ka hoʻoheheʻe ʻana, ka palpitations, ka piʻi ʻana o ke koko, arrhythmia, ka hiamoe, ke kuʻi ka huhū, ka huhū, ka huhū, ka lohi ʻana, ka manaʻo a me ka waha o ka maʻi, ka haʻalulu, ka ʻeha, ka hōʻino, ka bradycardia, ka nalowale o ka ʻike.

Me ka hypoglycemia maʻalahi me ka ʻike ʻole ʻole o ka ʻike, hoʻemi i ka nui o ka lāʻau o ka lāʻau a hoʻonui i ka nui o nā karoli e hāʻawi ʻia ana me ka meaʻai.

Inā loaʻa kahi kuhi hypoglycemic coma a i hopohopo ʻia, 50 ml o ka hopena o 40% glucose (dextrose) e kau ʻia (intravenously). Ma hope o ke kuhi ʻia, kahi 5% dextrose i hoʻopaʻa ʻia i ka intravenously, hiki iā ʻoe ke mālama i ke kaila o ka glucose i loko o ke koko (e pili ana iā ia ma kahi o 1 g / l).

Pono kiaʻi ʻia ka ʻike o ka glucose koko a kia hoʻomau mau ʻia ka mea maʻi i ka liʻiliʻi o 2 mau lā ma hope o ka loaʻa ʻana o kahi maʻi maʻi.

ʻO ka pono no ka nānā hou ʻana i nā hana nui a ka mea maʻi e hoʻoholo hou ʻia e kona kūlana.

No ka mea pili loa ka waiwai ikaika i nā protein plasma, ʻaʻole pono ka dialysis.

Kālā inoa Glyclazide MV, kumukūʻai i nā lāʻau lapaʻau

Inā pono, hiki iā ʻoe ke hoʻololi i ka Gliclazide MV me ka analogue i loko o ka hopena therapeutic - ʻo ia kēia mau lāʻau lapaʻau:

Ke koho nei i nā kikoʻī, pono ia e hoʻomaopopo i nā ʻōlelo no ka hoʻohana ʻana o Glyclazide MV, ke kumukūʻai a me nā loiloi, ʻaʻole pili mai i nā lāʻau lapaʻau me kahi hopena like. He mea nui ia e kamaʻilio pū me ke kauka kauka a ʻaʻole hoʻi e hana i kahi loli kūʻokoʻa kūʻokoʻa.

ʻO ke kumukūʻai ma nā kīhāpai Lūkini: Glyclazide MV 30 mg 60 papa - mai 123 a 198 mau rubles, Glyclazide MV 60 mg 30 mau papa - mai 151 a 210 mau rubles, e like me ka 471 mau lāʻau lapaʻau.

Store ma kahi pouli, mai kahi hiki o nā keiki i ka mahana a hiki i 25 ° C. ʻO 3 mau makahiki kahi ola i nā pale.

Lapaʻau

Hoʻonui i nā mea huna insulin e nā cell beta pancreatic a hoʻomaikaʻi i ka hoʻohana ʻana i ka glucose. Hoʻowalewale i ka hana o nā kinohi glycogen synthetase. Pōlaʻi i ka metabolic latent diabetes mellitus, i loko o nā mea maʻi me ka momona uluhua exogenously. Hoʻohālikelike i ka profile glycemic ma hope o kekahi mau lā o ka mālama ʻana. E hōʻemi ana i ka manawa manawa mai ka manawa o ka ʻai ʻana a hiki i ka hoʻomaka ʻana o ka huna ʻana o ka insulin, e hoʻihoʻi i ka mua o ka neʻe o ka huna ʻana i ka insulin a hoʻēmi ʻia i ka hyperglycemia i kumu o ka ʻai. Hoʻoulu i nā metala hematological, nā waiwai rheological o ke koko, ka mea kiʻekiʻe a me nā ʻōnaehana microcirculation. Kāleka i ka hoʻomohala ʻana o ka microvasculitis, ʻo ia hana ʻino o ka ʻina o ka maka. Kāohi i ka platelet aggregation, hoʻonui nui aʻe i ka pālahalaha kuleana index, hoʻonui i ka heparin a me ka hana fibrinolytic, hoʻonui i ka hoʻomanawanui heparin. Hōʻike i nā mea antioxidant, hoʻomaikaʻi i ka vascularization conjunctival, hoʻolako i ka holo koko mau loa i nā microvessels, e kāpae i nā hōʻailona o ka microstasis. Me ka nephropathy maʻi maʻi, ua hoʻemi ʻia ka proteinuria.

I nā hoʻokolohua ma ka hoʻopaʻa ʻana i nā maʻi o nā ʻano a me nā ʻano o ka maʻi o ka maʻi, ʻaʻohe hōʻailona o ka carcinogenicity, mutagenicity a me ka teratogenicity (nāu, nā kelepona), a me nā hopena i ka hānai (i nā kahe) i hōʻike ʻia.

Hoʻopau a wikiwiki koke i ka hoʻowalewale ʻana, C_max hoʻokō ma hope o 2-6 mau hola (no nā papa me ka hoʻokuʻu ʻia - ma hope o 6-12 mau hola) ma hope o ka hoʻokele ʻana. Hoʻokumu ʻia kahi kaila plasma equilibrium ma hope o 2 mau lā. ʻO ka pilina ʻana i ka protein plasma he 85-99%, ʻo ka nui o ka hoʻoili ʻana he 13-24 l. ʻO ka lōʻihi o ka hana me kahi paona hoʻokahi he 24 mau hola (no nā papa me ka hoʻokuʻu ʻia - ʻoi aku ma mua o 24 mau hola). I loko o ka puʻuwai, e hamo ana ia i ka maʻi oxidation, hydroxylation, glucuronidation me ka hoʻokumu ʻana o 8 mau metabolite hana ʻole, ʻo ia kekahi o ka hopena o ka microcirculation. Hoʻohui ʻia ia i ke ʻano o nā metabolites me ka urine (65%) a ma o ke kūnea ʻana (12%). T_1/2 - 8-12 mau hola (no nā papa me ke hoʻokuʻu ʻia - e pili ana i 16 mau hola).

Nā hopena hopena o ka waiwai Glyclazide

Mai ka hāliʻi ʻana o ka huina: loa loa - nā maʻi dyspeptic (nausea, luaʻi, ka ʻōpū o ka ʻōpū), ʻaʻole liʻiliʻi loa - jaundice.

Mai ka pūnaehana cardiovascular a me ke koko: cytopenia hoʻohala, eosinophilia, anemia.

Ma ka ʻāpana o ka ʻili. lohi - pale kūlohelohe ʻili, photosensitivity.

Mai ka ʻaoʻao o ka metabolism: hypoglycemia.

Mai ka pūnao a me ka hoʻonaninani naʻauao: nāwaliwali, māhuahua, luhi, hoʻololi i ka ʻono.

Hoʻohui

Hopena mahuahua o ACE nā mea kūpale, anabolic steroid, Hoʻokolohua-blockers, fibrates, biguanides, chloramphenicol, cimetidine, coumarin, fenfluramine, fluoxetine, salicylates, guanethidine, Mao nā mea kūpale, miconazole, fluconazole, pentoxifylline, theophylline, phenylbutazone, phosphamide, tetracyclines.

Barbiturates, chlorpromazine, glucocorticoids, sympathomimetics, glucagon, saluretics, rifampicin, hormones thyroid, lithium salts, nā koina kiʻekiʻe o ka waikawa nikotiniki, nā mea hoʻohālikelike a me ka estrogens - nāwaliwali hypoglycemia.

Ke keu

Nā Hoʻomaka ʻO nā kūlana hypoglycemic, a coma, edema cerebral.

Lāʻau: ka hoʻā o ka glucose i loko, inā pono - i loko o ka / i ka hoʻomaka ʻana o kahi ʻōhua o ka glucose (50%, 50 ml). Ka nānāʻana i ka glucose, urea nitrogen, seroly electrolytes. Me ka edema serebral - mannitol (iv), dexamethasone.

Niea ʻO Glyclazide

I ka wā koho o ka pākaukau, ʻoiai me ka hoʻohui pū ʻana me ka therapy insulin, pono ia e hoʻoholo i ke kōpīʻai gula a me ka hoʻohālike o ka glycemia, i ka wā e hiki mai ana ka mālama pinepine ʻana i nā pae glucose koko. No ka pale ʻana o ka hypoglycemia, pono ia e hoʻopili maoli me ka hoʻopili ʻana i ka meaʻai, a pale aku i ka pōloli a haʻalele pono i ka hoʻohana ʻana i ka inu wai. Hiki i ka hoʻohana ʻana i ka beta-blockers ke uhi i nā hōʻailona o ka hypoglycemia. Hoʻomaopopo ʻia kahi meaʻai ʻai liʻiliʻi-haʻahaʻa. E hoʻohana me ka akahele aʻo ka hana ʻana no nā mea hoʻokele o nā kaʻa a me nā poʻe e pili pū ana i ka hoʻoulu ʻana o ka makaʻala.

E hoʻokuʻu i ke ʻano a me ka ʻano

Hoʻololi ʻia ka Gliclazide MV i ke ʻano o nā papa me ka hoʻokuʻu ʻia: cylindrical, biconvex, keʻokeʻo me kahi ʻono ʻalani a i ʻole keʻokeʻo paha, hiki i nā ʻāpana marbling (10, 20 a i ʻole 30 mau ʻāpana i loko o ka alumini contour a i nā pōpoki polū polyvinyl chloride, 1, 2, 3, 4, 5, 6, 10 mau pākeke i kahi pōpō kāleka, 10, 20, 30, 40, 50, 60, a i ʻole 100 mau poloka.

Aia ka hoʻonohonoho ʻana o ka papa pākuhi 1:

ʻO ka waiwai koʻikoʻi: gliclazide - 30 mg,
ʻO nā mea kōkua: hypromellose - 70 mg, colloidal silicon dioxide - 1 mg, microcrystalline cellulose - 98 mg, magnesium stearate - 1 mg.

Lapaʻau lāʻau

ʻO Glyclazide kahi derphative o ka sulfonylurea ka mea he hypoglycemic waiwai a manaʻo ʻia no ka hoʻokō waha. ʻO ka ʻokoʻa mai nā lāʻau lapaʻau ma kēia ʻāpana, ʻo ke kahe ana o kahi apo heterocyclic N-loaʻa me ka mea paʻa endocyclic.

Hoʻopau ka Gliclazide i ke koko glucose, ka mea e hōʻeuʻeu i ka hana insulin e nā beta beta o nā mokupuni o Langerhans. Ke hoʻonui nui nei o ka C-peptide a me ka insulin postprandial e kū nei ma hope o 2 mau makahiki o ka mālama ʻana. E like me nā mea like o nā derebatives sulfonylurea, ʻo kēia hopena ma muli o ke ʻano ikaika loa o ka cells-cell o nā mokupuni o Langerhans i ka hōʻeuʻeu ʻana i ka glucose, i hana ʻia e like me ke ʻano physiological. ʻAʻole pili wale ka Gliclazide i ka metabolism ketone, akā ua hoʻonāukiuki i nā hopena hemovascular.

I ka poʻe maʻi me ka diabetes mellitus type 2, kōkua ke gliclazide e hoʻihoʻi i ka mua o ka hoʻokolohua o ka hana o ka insulin, kahi hopena o ka hoʻopiʻi glucose a hoʻoulu hou i ka lua o ka hana o ka huna ʻana o ka insulin. Hoʻonui ʻia ka hoʻonui nui o ka synthesis insulin me ka pane ʻana i ka hoʻoulu ʻia e ka maʻi glucose a ʻai ʻole paha i ka meaʻai.

ʻO ka hoʻohanaʻana o gliclazide e hōʻemi i ka hopena o ka hoʻomohala ʻana i ka moku thrombosis liʻiliʻi ma o ka hana ʻana i nā hana hiki ke hoʻonāukiuki i ka hoʻomohala ʻana o nā hoʻopiʻi i nā maʻi me ka maʻi mellitus, he hōʻemi i loko o nā manaʻo o nā mea hoʻohālikelike platelet (thromboxane₂, beta-thromboglobulin), kahi pale o ka hōʻiliʻili o ka pā platelet a me ka hōʻuluʻulu ʻana, me ka hoʻopiʻi ʻana i ka hoʻihoʻi hou ʻana o ka hana fibrinolytic ʻano o ka votone endothelium, a me ka hoʻonui ʻana i ka hana o plasminogen, he mea hoʻoikaika ka iwi.

ʻO ka hoʻohana ʻana o ka glycazide i hoʻokuʻu ʻia, ka target o ka hemoglobin glycosylated (HbAlc) i hōʻemi ʻia i ka 6.5%, i hāʻawi ʻia i ka mana glycemic kūlike e like me ka hoʻoliʻi kūloko kūlike e hōʻemi i ka hopena o ka macro- a me nā hoʻopiʻi microvascular i hoʻopili ʻia i ke ʻano type diabetes 2 i hoʻohālikelike ʻia i ka glycemic kūlohelohe. control

ʻO ka hana ʻana o ka mana glycemic intensive ka mea i kuhikuhi i ka gliclazide (ʻo ka awelika o ka lā maʻamau e 103 mg) a me ka hoʻonui ʻana i kona momona (a hiki i ka 120 mg i kēlā me kēia lā ke hele i ke ʻano maʻamau o ka maʻi ma ka ʻaoʻao (a i ʻole ʻoi aku) ma mua o ka hoʻohui ʻana iā ia me kekahi lāʻau lapaʻau hypoglycemic (ma ka laʻana, ka insulin, metformin thiazolidinedione derivative, alpha glucosidase inhibitor). ʻO ka hoʻohana ʻana o gliclazide i ka hui o nā mea maʻi e lawe ana i ka kontrol glycemic intensive (ma ka awelika, ʻo ka waiwai HbAlc o 6.5% a me ka nui o ka lōʻihi o ka nānā ʻana he 4.8 mau makahiki), i hoʻohālikelike ʻia me ka hui o nā mea maʻi e hoʻomalu nei i ka mālama maʻamau (ʻo ka makeʻana o ka HbAlc waiwai he 7,3% ), ua hōʻoia e pili ana ka hoʻohaʻahaʻa kūpono o ka hōʻuluʻulu ʻana o ka hoʻopiʻi a me ka hoʻopiʻi macrovascular mauʻu (e ka 10%) ma muli o ka hōʻemi nui ʻana o ka hopena pili i ka hoʻomohala nui ʻana o nā hoʻopiʻi microvascular nui (ma ka 14%), nā manawa Itijah a me ka Holomua o microalbuminuria (9%),ʻaʻa puʻuwai complications (11%), hoouka kaua a me ka Holomua o nephropathy (21%), a me ka hooulu ana o macroalbuminuria (30%).

Ke koho ʻana i ka gliclazide, loaʻa i ka maʻi glycemic intensive ka loaʻa o nā pono nui i hoʻoholo ʻole ʻia e nā hopena o ka mālama ʻana me nā lāʻau antihypertensive.

Lapaʻau lāʻau

Ma hope o ka lawelawe waha, ua hoʻokomo ʻia ke glycoside i ka hana kūwili e 100%. Hoʻonui mālie kona aniani i ka holo o 6 mau hola mua, a mau ka neʻe ʻana no ka 612 mau hola. ʻO ka laulā a i ʻole ka helu o ka hoʻopili ʻana o ka gliclazide ke kūʻokoʻa nei i ka ʻai o ka meaʻai.

Ma kahi o 95% o ka mea hana e hoʻopaʻa ai i nā protein plasma. ʻO ka nui o ka hoʻoili e pili ana i 30 mau lita. ʻO ka ʻike ʻana o Gliclazide MV ma kahi he 60 mg hoʻokahi i ka lā hoʻokahi e hiki iā ʻoe ke mālama i ka naʻau therapeutic o gliclazide i loko o ke koko koko no 24 mau hola a keu paha.

Hoʻopau nui ka hana gliclazide i loko o ka puʻuwai. ʻAʻole hoʻoholo ʻia ka pharmacologically hoʻoikaika o kēia mea i ka plasma. Hoʻolaha nui ʻia ka Gliclazide ma o nā ʻōpū ma loko o ke kinipona i loko o ke ʻano o nā metabolites, kahi kokoke i 1% i hoʻoponopono ʻia i ka urine. ʻO ka hapalua hapalua he 16 mau hola (ke hoʻololi ka hōʻailona mai ka 12 a 20 mau hola).

Ua hoʻopaʻa ʻia ka pilina laina ma waena o ka loaʻa o ka lāʻau lapaʻau (ʻaʻole iʻoi aku ma mua o 120 mg) a me ka wahi i lalo o ka curacokinetic curve "concentration - manawa". I ka poʻe maʻi ma waena, ʻaʻohe mau loli nui i ka maʻi i loko o nā laina pharmacokinetic.

Nā Hoʻohui

ʻO ka maʻi diabetes mellitus 1 (ke hilinaʻi-insulin),
ʻO kaʻeha hōʻeha o ke akepaʻa a me nā ukana,
Ketoacidosis
ʻO ka coma maʻi maʻi a me ka precoma
Hoʻohana me ka deridatives imidazole (me ka miconazole),
Hypersensitivity i sulfonamides a me sulfonylureas.

ʻAʻole hoʻohana ʻia ka hoʻohana ʻana o Glyclazide MV no ka lactating a me nā wahine hāpai.

Nā ʻōkuhi no ka hoʻohana ʻana i ka Gliclazide MV: kaʻina a me ka helu ʻana

Lawe ʻia ka Gliclazide MV ma mua o ka papaʻaina.

ʻO ka hoʻonui pinepine ʻia o ka lawe lāʻau i 2 mau lā i ka lā.

E hoʻoholo ana ke kauka i ka laʻikahi i kēlā me kēia lā, ma ke ʻano o nā hōʻike lapaʻau o ka maʻi a me ka glycemia, ma kahi ʻōpū ʻole a me 2 mau hola ma hope o kahi pāʻina.

Ma ke ʻano he kānāwai, ʻo ka dosis mua loa he 80 mg i kēlā me kēia lā, ʻo ka awelika awelika he 160-320 mg i kēlā me kēia lā.

Nā ʻōlelo kikoʻī

I ka mālamaʻana i ka mellitus non-insulin-hilinaʻi, pono e hoʻohana like ʻo Gliclazide MV i ka manawa like me ka meaʻai haʻahaʻa-calorie me kahi haʻahaʻa haʻahaʻa o nā calcium.

I ka wā mālama, pono ʻoe e kiaʻi pinepine i nā kukuna o kēlā me kēia lā i nā pae glucose, a me ka pae o ka glucose i loko o ke koko ma kahi ʻōpū ʻole a ma hope o ka ʻai.

Me nā interventions kaʻaila a i ʻole decompensation o ka mellitus o ka maʻi mellitus, pono ke noʻonoʻo pono ʻia ka hoʻohana ʻana i ka hoʻomākaukau o ka insulin.

I ka hihia o ka hypoglycemia, inā ua ʻike ka mea maʻi, he glucose (a he ʻaila gula paha) e hoʻohana ʻia me ka ʻōlelo maʻamau. Ma kahi e pau ai ka ʻike, glucose (intravenously) a i ʻole glucagon (subcutaneously, intramuscularly a intravenously) paha e lawelawe. I mea e pale ai i ka hoʻomohala hou ʻana o ka hypoglycemia ma hope o ka hoʻihoʻi ʻana i ka ʻike, pono ke hāʻawi ʻia ka mea maʻi i nā meaʻai momona.

ʻAʻole hoʻohana ʻia ka hoʻohana pinepine ʻana o gliclazide me cimetidine.

Me ka hoʻohana pū ʻana o ka gliclazide me ka verapamil, pono ia e kiaʻi pinepine i ka pae o ka glucose i ke koko, me ka acarbose, ka nānā akahele a me ka hoʻoponopono ʻana i ka hoʻoponopono ʻia ʻana o nā hana a ka lawehala o ka hypoglycemic pono.

Hoʻokomo i ka hiki ke lawe i nā kaʻa a me nā mīkini paʻakikī

ʻO ka poʻe maʻi e lawe ana iā Glyclazide MV pono e ʻike i nā hōʻailona hiki i ka hypoglycemia a ua haʻi aku e pili ana i ka pono e makaʻala i ka wā e hoʻokele a hana ana i kekahi mau hana e koi ai i nā ʻano psychomotor koke, me ka hoʻomaka ʻana o ka mālama ʻana.

ʻŌpū a me ka lactation

ʻAʻoheʻike iʻike me ke koho ʻana o ka Gliclazide MV i nā wahine hāpai. ʻAʻole hōʻoia nā haʻawina i nā holoholona i ka hele ʻana o nā hopena teratogenic o kēia ʻano. Me ka lawa ʻole o ka uku ʻana no ka diabetes mellitus i ka wā mālama, loaʻa ka hopena i ka ulu ʻana o ka nui o nā mau huaʻāina i loko o ka pūpū, kahi e hiki ai ke hōʻemi ʻia e ka mākaʻi glycemic kūpono. Ma kahi o gliclazide i nā wahine hāpai, ua kuhikuhi ʻia e hoʻohana i ka insulin, ʻo ia hoʻi ka lāʻau lapaʻau ke koho pono ʻana no nā maʻi e hoʻolālā nei i kahi hapai, a i nā mea hoʻi i hāpai i ka wā mālama me ka Gliclazide MV.

No ka mea, ʻaʻohe ʻike e pili ana i ka komo ʻana o ka hana ikaika o ka lāʻau i ka waiū umauma, a ma nā mea hānau keiki hou, he nui ka nui o ka ulu ʻana o ka hypoglycemia neonatal, ka lawe ʻana i ka Gliclazide MB i ka wā lactation a contraindicated.

Hoʻohui nūhou

Me ka hoʻohana pū ʻana o Gliclazide MV me kekahi mau lāʻau lapaʻau, hiki i nā hopena kūpono ʻole:

Nā derivava Pyrazolone, salicylates, phenylbutazone, sulfonamides antibakteri, theophylline, caffeine, monoamine oxidase inhibitors (MAOs): potentiation o ka hopena hypoglycemic o glyclazide,
ʻO nā beta-blockable non-koho: hoʻonui nui aʻe o ka hypoglycemia, hoʻonui nui ʻana a me ka masking o ka tachycardia a me nā lima pākuʻi i hōʻike ʻia o ka hypoglycemia,
ʻO Gliclazide a me ka acarbose: hoʻonui i ka hopena hypoglycemic,
Cimetidine: hoʻonui i ka kukuna plasma gliclazide (ulu ulu hypoglycemia, hōʻike ʻia i loko o ke ʻano o ka hopohopo o ke kikowaena o ka pūnaehana a me ka ʻike naʻau),
ʻO nā Glucocorticosteroids (me nā puka i waho o nā ʻano aʻi aku), diuretics, barbiturates, estrogens, progestin, hui pū kekahi estrogen-progestogen, diphenin, rifampicin: kahi hōʻemi i ka hopena hypoglycemic o ka glycazide.

ʻO nā analogues o Gliclazide MV lākou: Gliclazide-Akos, Glidiab, Glidiab MV, Glucostabil, Diabeton MV, Diabefarm MV, Diabinax, Diabetalong.

Nā Hōʻikeʻike i ka Gliclazide MV

ʻO Gliclazide MV no ka derivatives sulfonylurea o ka lua o ka hanauna a ke hōʻike ʻia nei e kahi nui koʻikoʻi o nā hana hypoglycemic, kahi i wehewehe ʻia e kahi kiʻekiʻe kiʻekiʻe no nā ʻae-cell-cell (2-5 mau manawa i ʻoi aku ma mua o ka hanauna o nā lāʻau lapaʻau). Hāʻawi kēia mau waiwai iā ʻoe e hoʻokō i kahi hopena therapeutic me nā dosis liʻiliʻi a hōʻemi i ka nui o nā hopena maikaʻiʻole.

Wahi a nā loiloi, hoʻohana ʻia ʻo MV Gliclazide no ka hoʻopiʻi ʻana i ka maʻi diabetes mellitus (retinopathy, nephropathy me ka hoʻomaka ʻana o kahi renal maʻi maʻamau, angiopathy). Ua hōʻike ʻia kēia ma nā mea maʻi i lawe ʻia e loaʻa i kēia lāʻau lapaʻau. ʻO kēia no ka mea, ʻo kekahi o nā metabolits glycazide e hoʻopilikia nui i ka microcirculation, hoʻemi i ka hōʻeha o ka angiopathy a me ka pilikia o ka hoʻomohala ʻana i nā hoʻopiʻi microvascular (nephropathy a me ka retinopathy). I ka manawa like, hoʻomaikaʻi hou ke kahe koko i loko o ka conjunctiva a nalowale nā vascular stasis.

Hoʻolaha nā loea he nui i ka wā o ka mālama ʻana me Gliclazide MV, pono e pale i ka pōloli a hāʻawi i ka makemake i nā meaʻai me nā momona. Inā ʻaʻole, i ka wā o ke kīhina o kaʻai haʻahaʻa o ka lālani a ma hope o ka hoʻoikaika kino loa, hiki i ka mea maʻi ke hoʻomohala i ka hypoglycemia. Me ke kaumaha o ke kino, pono ke hoʻoponopono ʻia. I kekahi mau mea maʻi, ma hope o ka inu ʻana i ka waiʻona i ka wā o ka mālama ʻana me Gliclazide MV, ua ʻike pū ʻia nā hōʻailona o ka hypoglycemia.

ʻAʻole i ʻōlelo ʻia ʻo Gliclazide MV no ka hoʻohana ʻana i nā maʻi maʻi elemakule e ulu aʻe ana no ka ulu ʻana o ka hypoglycemia, no laila, i kēia hihia, kūpono ke hoʻohana i nā lāʻau lapaʻau ʻōkole.

Hoʻomaopopo ka poʻe maʻi i ka hōʻoluʻolu o ka hoʻohana ʻana i ka gliclazide i ke ʻano o nā papa hoʻoneʻe i hoʻololi ʻia: hana maʻalahi lākou, a ke kāʻei wale ʻia ka mea hana a pau ma ke kino. Ma muli o kēia, hiki ke lawe ʻia ka lāʻau lapaʻau i hoʻokahi manawa i kēlā me kēia lā, a ʻo kāna hōʻola a me nā lā therapeutic he 2 mau manawa e emi iho ai ma mua o kahi ʻano gliclazide maʻamau. Aia nō hoʻi nā hōʻike e pili ana i ka hoʻomehana lōʻihi (3-5 mau makahiki mai ka hoʻomaka ʻana o ka hoʻokele), i hoʻomohala kekahi mau mea maʻi, e koi ai i ka hana ʻana o nā lāʻau lapaʻau hou.

ʻLoe a me ke kākele

Ka hoʻoholo ʻia ʻana o ka nui o ka lāʻau lapaʻau e ke kauka hele mai. Ma kēia hihia, ʻo ka makahiki o ka mea maʻi, ka hele a me ka hōʻeha o nā hōʻailona ma ke ʻano o ka maʻi, a me ka lā wikiwiki glycemia e koi ana a me nā hola 2 ma hope o ka pāʻina ʻana.

E like me nā kauoha no Gliclazide, ʻo ka 100 mg mua o kēlā me kēia lā he 80 mg, ka awelika he 160 mg, ʻo ka ʻokoʻa loa ka 320 mg. Pono ke kinona i ka lālani i ʻelua mau manawa i ka lā 30-60 mau minuke ma mua o ka pāʻina.

ʻO ka ʻōmua mua o MV Glyclazide he 30 mg. Inā lawa ka hopena therapeutic e like me ka manawa hoʻokahi i kēlā me kēia 2 hebedoma, hiki ke hoʻonui pinepine ʻia ka nui i loko o kahi lā nui loa o nā lā he 120 mg (4 papa).